Battle of the blood clots: Tailored glycopolymers as anticoagulant heparin mimetics

Oct 11, 2013

(Phys.org) —One of the risks of any large operation is the occurrence of blood clots. To prevent this, patients are routinely given the anticoagulant heparin or related drugs. American scientists have now introduced a new approach to the production of synthetic heparin mimetics with better activity profiles.

Heparin has been used as an anticoagulant since 1935 to both treat and prevent the that can result from operations, blood transfusions, or dialysis. Heparin is a substance produced by the body and consists of long chains of sugar (saccharide) molecules. The sugar building blocks contain a large number of sulfate groups.

Because heparin is obtained from , its use does pose some problems. Contamination may lead to . Furthermore, batches of the drug are often not homogeneous so the effectiveness of a given dose must be calculated case by case. In about 3 % of patients, long-term treatment with heparin leads to a dangerous autoimmune disease. Low-molecular-weight drugs such as Arixtra, which contains only five sugar groups, have been developed as an alternative. Their disadvantage is the very complex and expensive process used to make them.

Linda C. Hsieh-Wilson and her team at the California Institute of Technology in Pasadena have now uncovered an interesting new angle: synthetic glycopolymers, long chains of molecules that have as side groups. The researchers chose to use two sugars typically found in heparin as side groups. One of these sugars was equipped with an additional sulfate group. The synthesis of such glycopolymers is much simpler than the synthesis of natural polysaccharides, but it is still a complex undertaking, and it is made more difficult in this case because of the need to attach sulfate groups in a controlled fashion. The team was able to use a ring-opening metathesis polymerization reaction (ROMP) to make polymer chains of varying length with a maximum of 45 units.

The longer molecular chains demonstrate stronger activity than anticoagulants currently in clinical use. The additional sulfate group is critical to this effectiveness. Interestingly, systematic changes to the length of the chain and pattern of sulfate groups allow for fine-tuning of the effect. This makes it possible to make drugs with different activities from those previously in clinical use. For example, the glycopolymer containing 45 building blocks targeted the two major branches of the blood coagulation cascade to a different extent than both the small molecule and polysaccharide drugs.

Explore further: Moving single cells around—accurately and cheaply

More information: Hsieh-Wilson, L. Tailored Glycopolymers as Anticoagulant Heparin Mimetics, Angewandte Chemie International Edition. dx.doi.org/10.1002/anie.201306968

add to favorites email to friend print save as pdf

Related Stories

US issues guidelines to avoid heparin contamination

Feb 10, 2012

Four years after US drug-maker Baxter International's blood thinner heparin was contaminated in China, causing dozens of deaths, US regulators on Friday issued draft guidelines for safe production.

Toward an improved test for adulterated heparin

Sep 21, 2011

Scientists are reporting refinement of a new test that promises to help assure the safety of supplies of heparin, the blood thinner taken by millions of people worldwide each year to prevent blood clots. The ...

Researchers create new synthetic heparin

Sep 21, 2007

Researchers at the University of North Carolina at Chapel Hill have patented a synthetic version of the drug heparin, called Recomparin, that is less complex chemically and should be easier to produce than previous forms.

Recommended for you

Moving single cells around—accurately and cheaply

10 hours ago

Scientists at the Houston Methodist Research Institute have figured out how to pick up and transfer single cells using a pipette—a common laboratory tool that's been tweaked slightly. They describe this ...

The difficult question of Clostridium difficile

13 hours ago

The bacterium Clostridium difficile causes antibiotic-related diarrhoea and is a growing problem in the hospital environment and elsewhere in the community. Understanding how the microbe colonises the hu ...

New technology offers insight into cholesterol

Aug 14, 2014

With new advanced techniques developed by the Copenhagen Center for Glycomics at the University of Copenhagen it is possible to study cells in greater detail than ever before. The findings have just been ...

User comments : 0